Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/imunon-inc">Imunon </a>is a clinical-stage biotechnology company whose value is primarily driven by its lead candidate, IMNN-001, a novel DNA-based immunotherapy for advanced ovarian cancer currently in a pivotal Phase 3 trial (OVATION 3).</li>
  <li>Recent Phase 2 (OVATION 2) data for IMNN-001 is highly encouraging, showing a median overall survival benefit of 14.7 months when added to standard chemotherapy, and a 24.2-month benefit in patients who also received PARP inhibitors.</li>
  <li>The company is pre-revenue and faces significant financial risk, relying on capital raises to fund its operations and expensive clinical trials. Recent financing has been secured, but the capital environment remains challenging.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Imunon is a clinical-stage biotechnology company whose value is primarily driven by its lead candidate, IMNN-001, a novel DNA-based immunotherapy for advanced ovarian cancer currently in a pivotal Phase 3 trial (OVATION 3).
  Recent Phase 2 (OVATION 2) data for IMNN-001 is highly encouraging, showing a median overall survival benefit of 14.7 months when added to standard chemotherapy, and a 24.2-month benefit in patients who also received PARP inhibitors.
  The company is pre-revenue and faces significant financial risk, relying on capital raises to fund its operations and expensive clinical trials. Recent financing has been secured, but the capital environment remains challenging.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

United States

IMUNON, Inc. operates as a clinical stage biotechnology company. The Company focuses on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Imunon (IMNN US)

Primer: Imunon (IMNN US) - Aug 2026

Imunon is a clinical-stage biotechnology company whose value is primarily driven by its lead candidate, IMNN-001, a novel DNA-based...

αSK Primers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)